In preclinical models, treatment with a glucose transporter (GLUT) inhibitor can effectively inhibit glucose uptake, induce disulfidptosis in SLC7A11high-expressing cancer cells, and limit the growth of SLC7A11high cancer cells, such as UMRC6 kidney cell carcinoma xenografts in mice, which highlights the need for the development of cancer treatment strategies (8, 9). Here, SLC2A1 is linked to cancer.